

GDP per capita

(PPP int'l dollars) WDI (2022)

\$39,280

Living in poverty

(Under \$2.15 int'l dollars / day) WDI (2022)

1%

Gvernment health spending as % of GDP7

WHO GHED

6%

Life expectancy at birth

(Years) WDI (2022)

76.8

Maternal mortality ratio

(per 100,000 live births)

50


Neonatal mortality

(Per 1.000 live births)

Premature NCD mortality²

(Probability) WHO

11%



Communicable and Other Injuries

- Note: Indicator values presented here may differ from country data sources due to the use of standardized categories and methods to enhance international comparability. See indicator Description Sheet for details
- Note: Scores for the Capacity, Performance, and Equity domains are color-coded to reflect good (green), medium (vellow). and poor (red) performance, where comparable data are available. Cut-offs can be found in the Indicator Description Sheet. al 4 (alto) Scores based on data from non-comparable sources are colored gray. Finance indicators are not color-coded because these 4. Dado que en cada país se utilizan diferentes datos / indicadores, es posible que los valores del indice compuesto no
- - sean comparables entre países. Consulte la página 2 para conocer los indicadores específicos utilizados en este PSV.

 5. El índice de cobertura compuesto refleja la cobertura de 3 intervenciones de salud matema e infantil (partos atendidos por profesional de
- 6. Muertes de niños antes de los 5 años por cada 1.000 nacidos vivos (INEC 2021)
- Gasto nacional en salud del gobierno general como porcentaje del producto interno bruto (PIB) 8. Probabilidad de morir entre los 30 y los 70 años de edad por enfermedad cardiovascular, cáncer, diabetes o enfermedad respiratoria crónica
- Última actualización 11/2023



DOMINIO DE CAPACIDAD: INDICADORES DEL PERFIL DE SIGNOS VITALES

Panama	SCORE
GOVERNANCE	2.4
Governance and Leadership	2.4
Measure 1: Primary health care policies (1/2)	
Measure 2: Primary health care policies (2/2)	
Measure 3: Quality management infrastructure	
Measure 4: Social accountability (1/2)	
Measure 5: Social accountability (2/2) Adjustment to Population Health Needs	2.3
Measure 6: Surveillance	2.3
Measure 7: Priority setting	
Measure 8: Innovation and learning	
INPUTS	2.4
Drugs and Supplies	2.3
Measure 9: Stock-out of essential medicines	
Measure 10: Basic equipment availability	
Measure 11: Diagnostic supplies	
Facility Infrastructure	2.3
Measure 12: Facility distribution	
Measure 13: Facility amenities	
Measure 14: Standard safety precautions and equipment Information Systems	2.7
Measure 15: Civil Registration and Vital Statistics	2.7
Measure 16: Health Management Information Systems	
Measure 17: Personal care records	
Workforce	2.8
Measure 18: Workforce density and distribution	
Measure 19: Quality assurance of primary health care workforce	
Measure 20: Primary health care workforce competencies	
Measure 21: Community health workers	
Funds	2.0
Measure 22: Facility budgets	
Measure 23: Financial Management Information System	
Measure 24: Salary payment POPULATION HEALTH AND FACILITY MANAGEMENT	
Population Health Management	2.2
Measure 25: Local priority setting	2.0
Measure 26: Community engagement	
Measure 27: Empanelment	
Measure 28: Proactive population outreach	
Facility Organization and Management	2.4
Measure 29: Team-based care organization	
Measure 30: Facility management capability and leadership	
Measure 31: Information system use	
Measure 32: Performance measurement and management (1/2)	
Measure 33: Performance measurement and management (2/2)	



Panama	SCORE	PERCENTAGE	SOURCE YEAR	
ACCESS	72			
Financial	12			
Perceived access barriers due to treatment costs*		25%	ENSPA 2019	
Geographic		2370	LIISI A 2013	
Barreras de acceso percibidas debido a la distancia*		31%	ENSPA 2019	
Tiempo		5276	210171 2020	
Tiempo de espera menor de 30 minutos para consultas ambulatorias		28%	ENSPA 2019	
QUALITY	53			
Comprehensiveness				
Avg. availability of 5 tracer RMNCH services		No data available		
Avg. availability of 5 tracer kinners services Avg. availability of services for 3 tracer communicable diseases		No data available		
Avg. availability of diagnosis & management for 3 tracer NCDs		No data available		
Continuity		3444 474144514		
DTP3 dropout rate*		11%	EPI - Expanded Program on Immunization 2021	
Treatment success rate for new TB cases		76%	WHO TB Profile 2022	
Notification rate of laboratory results		86%	ENSPA 2019	
Person-Centeredness				
Perceived quality of outpatient care		88%	ENSPA 2019	
Perceived health outcomes of outpatient care		91%	ENSPA 2019	
% of caregivers who were told sick child's diagnosis		No data available		
Provider availability				
% of outpatient visits over 10 minutes**		32%	ENSPA 2019	
Provider absence rate* (%)		No data available		
Provider Competence				
Antenatal care quality score**		32%	ENSPA 2019	
Family planning quality score**		34%	ENSPA 2019	
Sick child quality score		No data available		
Adherence to clinical guidelines		No data available		
Appropriate screening in children less than 1 year old**		67%	MINSA 2021	
Diagnostic accuracy		No data available		
Security				
Adequate waste disposal		No data available		
Ad equate infection control		No data available		
Perceived conditions of healthcare facilities		66%	ENSPA 2019	
First Contact Access				
Outpatient visits for routine or follow-up care		85%	ENSPA 2019	
SERVICE COVERAGE	70			
Reproductive, Maternal, Newborn and Child Health				
Demand for family planning satisfied with modern methods(%)		73%	WHO - UHC Monitoring (UHC report	2023), data 2021
Antenatal care coverage (4+ visits)		99%	WHO - UHC Monitoring (UHC report	
Coverage of DTP3 immunization		74%	WHO - UHC Monitoring (UHC report	2023), data 2021
Children aged < 5 years with pneumonia symptoms taken to a healthcare pro	vider	82%	WHO - UHC Monitoring (UHC report	2023), data 2021
Reproductive, Maternal, Newborn and Child Health			<u> </u>	
Tuberculosis cases detected and treated with success (%)		80%	WHO - UHC Monitoring (UHC report	2023), data 2021
People living with HIV receiving anti-retroviral treatment (TAR)		66%	MINSA, UNAIDS 2022	
Children aged < 5 years with diarrhea receiving ORS in health facilities		No data available		
Non-Communicable Diseases (NCDs)				
Prevalence of treatment among adults with hypertension (%)***		55%	WHO - UHC Monitoring (UHC report	2023), data 2021

*Indicators where lower values are preferable were transformed before inclusion in the index. The modified indicator was defined as 100-X, where X is the original percentage shown in this table. **Country-specific (proxy) indicator, used in absence of globally comparable survey data. ***UHC 2023 reported number based on WHO NCD Risk Group estimates (2021 data) for prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension.For more details see Tracking UHC: 2023 Global Monitoring Report. Note: Summary scores for the domains of Access, Quality, and Coverage are calculated by taking the average of indicator values within each subdomain, and then taking the average across subdomain scores.